echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The joint clinical study of Laikai and Innovent Bio was approved

    The joint clinical study of Laikai and Innovent Bio was approved

    • Last Update: 2022-01-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On January 10, Laikai Pharmaceuticals announced that its clinical phase I/II trial application for a combined treatment regimen for patients with anti-PD-1/PD-L1-resistant specific solid tumors has been approved by the CDE


    This "Phase I/II dose escalation and efficacy/safety study of auresertib+sintilimab+chemotherapy in patients with anti-PD-1/PD-L1-resistant specific solid tumors" was conducted by the associate hospital of Peking University Cancer Hospital.


    The goal of this study is to partially evaluate the safety of the above-mentioned three drugs in combination, determine the recommended dose for the Phase II study, and evaluate the clinical efficacy and safety of the combination therapy in the Phase II study


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.